Safety and Efficacy of DCB for the Treatment of SFA Ischemic Vascular Disease in Patients With TASC C and D Lesions

Overview

The study is aimed at collecting preliminary safety and efficacy data related to the use of Drug Coated Balloon (DCB) technology for the treatment of symptomatic Superficial Femoral Artery (SFA) ischemic vascular disease in patients presenting with long lesions. The present clinical evaluation is intended as a prospective observational data collection of patient treatment in full accordance with institution standard practice and utilizing an approved (CE marked) DCB currently available on the market.

Full Title of Study: “Safety and Efficacy of the Drug Coated Balloon (DCB) for the Treatment of the Superficial Femoral Artery (SFA) Ischemic Vascular Disease in Symptomatic Patients Presenting With TASC C and D Lesions: a Pilot Study”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: September 2017

Detailed Description

The present study is designed as a prospective, open label, observational study. The study will collect information about the medical care patients receive during their planned procedure. No additional testing or procedures will be done. Patients elected for endovascular revascularization with DCB will be asked their written consent to the use of their personal data. Revascularization will be performed as per standard procedure of the sites. After discharge all patients will attend clinic visits at 30 days (±14 days), 6 months (±30 days), 12 months (±30 days), 24 and 36 months (±30 days). Angiographic follow-up will be performed in symptomatic patients, as clinically indicated.

Interventions

  • Device: Drug Coated Balloon
    • Peripheral PTA with a drug coated balloon

Clinical Trial Outcome Measures

Primary Measures

  • Rate of primary patency
    • Time Frame: 12 months after percutaneous treatment
    • Primary patency is defined as freedom from the combined endpoints of clinically-driven target lesion revascularization (TLR) and >50% restenosis in the treated lesion.

Secondary Measures

  • composite of all Major Adverse Events (MAE)
    • Time Frame: 24 months after percutaneous treatment
    • Incidence of the composite of all Major Adverse Events (MAE) through 24 months
  • Incidence of Major Adverse Events (MAE)
    • Time Frame: 36 months after percutaneous treatment
    • Incidence of Major Adverse Events (MAE) through 36 months
  • Clinical improvement as assessed by Rutherford Class changes
    • Time Frame: 6, 12, 24 and 36 months vs baseline
    • Clinical improvement as assessed by Rutherford Class changes

Participating in This Clinical Trial

Inclusion Criteria

1. Documented obstructive ischemic, symptomatic arterial disease in the femoral-popliteal arteries according to Rutherford Category 2, 3 or 4 2. Target lesion consists of a single solitary or multiple adjacent de novo or re-stenotic lesions (non-in-stent) with diameter stenosis ≥ 70% by visual estimate and cumulative lesion length ≥ 15 cm 3. Target vessel is the superficial femoral artery and/or popliteal artery (P1-2-3) 4. Life expectancy >1 year in the Investigator's opinion 5. Written informed consent Exclusion Criteria:

1. Patient unwilling or unlikely to comply with FU schedule 2. Administration of local or systemic thrombolytic therapy within 48 hours prior to the index procedure 3. Known allergies or sensitivities to heparin, aspirin, other anticoagulant/antiplatelet therapies, and/or paclitaxel 4. Additional planned cardiac or peripheral percutaneous or surgical intervention including CABG within 30 days following the study procedure 5. ≥15 cm long inflow lesion (≥50% DS) 6. Failure to successfully treat < 15 cm long inflow lesion in the ipsilateral Iliac artery

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Ettore Sansavini Health Science Foundation
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Antonio Micari, MD, Principal Investigator, Maria Cecilia Hospital
  • Overall Contact(s)
    • Maria Salomone, MD, +390545217031, msalomone@esrefo.org

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.